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Abstract
The human tumour antigen PRAME (preferentially expressed antigen in melanoma) is frequently overexpressed during
oncogenesis, and high PRAME levels are associated with poor clinical outcome in a variety of cancers. However, the
molecular pathways in which PRAME is implicated are not well understood. We recently characterized PRAME as a BC-box
subunit of a Cullin2-based E3 ubiquitin ligase. In this study, we mined the PRAME interactome to a deeper level and
identified specific interactions with OSGEP and LAGE3, which are human orthologues of the ancient EKC/KEOPS complex. By
characterizing biochemically the human EKC complex and its interactions with PRAME, we show that PRAME recruits a Cul2
ubiquitin ligase to EKC. Moreover, EKC subunits associate with PRAME target sites on chromatin. Our data reveal a novel link
between the oncoprotein PRAME and the conserved EKC complex and support a role for both complexes in the same
pathways.
Citation: Costessi A, Mahrour N, Sharma V, Stunnenberg R, Stoel MA, et al. (2012) The Human EKC/KEOPS Complex Is Recruited to Cullin2 Ubiquitin Ligases by
the Human Tumour Antigen PRAME. PLoS ONE 7(8): e42822. doi:10.1371/journal.pone.0042822
Editor: Laszlo Tora, Institute of Genetics and Molecular and Cellular Biology, France
Received May 5, 2012; Accepted July 11, 2012; Published August 13, 2012
Copyright:  2012 Costessi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Work in the authors’ laboratories was funded by Dutch Cancer Society KWF (to HGS) and by Grant GM41628 from the National Institute of General
Medical Sciences (to RCC and JWC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: H.Stunnenberg@ncmls.ru.nl
Introduction
The human oncoprotein PRAME (preferentially expressed
antigen in melanoma) was first identified and cloned as the
antigen responsible for an anti-tumour immune response in a
melanoma patient [1]. Follow-up experiments revealed that
PRAME is expressed at low levels in few normal adult tissues
like adrenals, ovaries, and endometrium, and at high levels only
in the testis [1,2]. However, overexpression of PRAME is
frequently found in a wide variety of human cancers, including
acute and chronic haematological tumours, synovial sarcoma,
lung, breast, and renal carcinoma [1,3]. Importantly, high
PRAME levels were found to correlate with advanced stages of
disease in melanoma [4], neuroblastoma [5], serous ovarian
adenocarcinoma [6], and chronic myeloid leukaemia [7], and to
constitute an independent prognostic factor of poor clinical
outcome in breast cancer [8,9]. In contrast, high levels of
PRAME were found to correlate with good prognosis in
leukaemia cases carrying the t(15;17) PML-RAR translocation
(acute promyelocitic leukaemia) [10].
Although these findings suggested a role for PRAME in human
malignancies, the detailed molecular mechanisms and pathways
involved are not yet clear. PRAME was reported to repress
retinoic acid signaling in melanoma cell lines [11], but this was not
confirmed for breast cancer or leukaemia cases [9,12]. Conflicting
reports on leukaemia cells suggested that PRAME might induce
caspase-independent cell death [13], or repress apoptosis-related
genes to promote cell survival [14].
Recently, through biochemical characterization of PRAME-
containing protein complexes, we established that this oncoprotein
is a component of Cullin2-based E3 ubiquitin ligases and belongs
to the family of BC-box proteins, associating PRAME to a clear
biochemical activity and pathway [15]. PRAME establishes direct
interactions with other ligase subunits through conserved N-
terminal motifs: a BC-box (aa. 25–34) mediates interactions with
the ElonginB-ElonginC heterodimer, and a downstream Cul2-box
(aa. 48–56) mediates interactions with the Cullin2 scaffold protein.
Genome-wide chromatin immunoprecipitation experiments fur-
ther revealed that Cul2-PRAME ubiquitin ligases specifically
associate with active promoters regulated by the transcription
factor NFY and with proximal enhancers [15].
Two independent laboratories have identified an ancient and
highly conserved multiprotein complex named KEOPS [16] or
EKC [17], which has orthologues from Archaea to Eukarya and
has been implicated in telomeres maintenance, transcriptional
regulation, and t6A modification of tRNAs. Yeast EKC comprises
four subunits which are also conserved in the human genome
(human orthologues are indicated in brackets): Pcc1p (LAGE3,
also known as ESO3), the ATPase Kae1p (OSGEP), the kinase
Bud32p (TP53RK, also known as PRPK), and Cgi121p (TPRKB).
In addition, yeast EKC also includes Gon7p (also known as
Pcc2p), which appears to be fungi-specific [17].
Intriguingly, the OSGEP subunit is also present in bacteria
(YgjD) and eukaryotic genomes express an OSGEP paralogue
(Qri7/OSGEPL1) that localizes to mitochondria [18]. Compar-
ative genomic studies identified OSGEP as one of the very few
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genes present in all genomes sequenced so far [19], suggesting an
extremely conserved function. Very recently, several research
groups have reported a crucial role for the YgjD/Kae1/OSGEP
protein family in the biosynthesis of N6-threonylcarbamoyl
adenosine (t6A) [20–22]: a universal modification at position 37
of tRNAs decoding ANN codons, which is required for accurate
translation of messenger RNAs [23].
Human LAGE3 belongs to the NY-ESO gene family together
with the closely related LAGE1 and LAGE2 [24], and all three
genes are clustered in the same region on chromosome X. While
LAGE3 is ubiquitously expressed, LAGE1 and LAGE2 are
cancer-testis antigens with high expression in healthy testis and
upregulation in a number of cancer tissues, similarly to PRAME.
The aim of the present study was to mine the protein-protein
interactome of the PRAME oncoprotein to a deeper level by
protein complex purification and mass spectrometry. Our
experiments revealed that PRAME specifically interacts with the
EKC complex in human cells and that it recruits Cul2-based E3
ubiquitin ligases to EKC. We further show that EKC subunits co-
localize with PRAME at the promoter regions of transcriptionally
active human genes, supporting a common functional role for
these complexes on chromatin. Overall, our findings provide novel
and important insights in the molecular pathways in which the
oncoprotein PRAME is active.
Results
PRAME Interacts with the EKC/KEOPS Complex
We have recently applied biochemical purification strategies
and characterized PRAME as a component of Cullin2 E3
ubiquitin ligases [15]. Here, we improved the immunoaffinity
purification protocols and mined the PRAME interactome to a
deeper level (see materials and methods). We isolated epitope-
tagged PRAME (StrepII-Myc-3xHA-PRAME, referred to as
TAG-PRAME) from K562 cells, which express high levels of
endogenous PRAME, and from HeLaS3 cells, which express
endogenous PRAME at very low to undetectable levels. As
expected, mass spectrometry analysis of HA immunoprecipitates
detected Cullin2 ligase components with the highest emPAI:
Cullin2, Elongin B, Elongin C, and Rbx1 (Table 1). Notably,
western blot analysis showed that Cullin2 and Elongin C were
expressed to similar levels in nuclear extracts from the two cell
lines (not shown).
Furthermore, a number of additional proteins were specifically
detected in eluates of K562-TAG-PRAME and HeLaS3-TAG-
PRAME cells, but not in the control parental cell lines. These
included OSGEP (O-sialoglycoprotein endopeptidase) and
LAGE3 (L antigen family member 3), which are the human
orthologues of the Kae1 and Pcc1 subunits of the recently
described EKC complex (Table 1). OSGEP and LAGE3 were
present with a similar abundance in TAG-PRAME eluates from
both K562 and HeLaS3 cell lines, consistent with similar
expression levels. However, in these eluates we did not identify
peptides matching TP53RK or TPRKB, which are the predicted
human orthologues of the EKC subunits Bud32 and Cgi121,
respectively.
Other potential interactors identified in PRAME eluates were
BAG2 and UBL4A (Table 1). BAG2 (BAG family molecular
chaperone regulator 2) is a nucleotide exchange factor for the
chaperone protein Hsp70 that contributes to the processing of
misfolded proteins [25]. Similarly, UBL4A (Ubiquitin-like protein
4A) is part of a chaperone protein complex that promotes correct
membrane targeting of tail-anchored proteins [26,27]. Peptides for
both BAG2 and UBL4A were identified in all anti-HA eluates
from K562-TAG-PRAME cells, but were not detected in the anti-
MYC eluates. Additional experiments are therefore needed to
establish whether these proteins are real interactors of PRAME or
rather false positives. For the purpose of this study, we further
concentrated on EKC subunits.
The specificity of the interactions between PRAME and EKC
subunits was confirmed by transient transfections in HEK293T
cells and coimmunoprecipitation experiments of TAG-PRAME
with OSGEP and LAGE3 fused to a TTE (TY1-TY1-ER) epitope
tag (Fig. 1A). We also used a baculovirus expression system to co-
express FLAG-PRAME with different combinations of the four
human EKC subunits in Sf21 insect cells. Consistent with the
transient transfection experiments, we observed that PRAME
could bind to OSGEP and LAGE3 independent of TP53RK and
TPRKB. Interestingly, although both OSGEP and LAGE3 could
bind PRAME independent of the other (Fig. 1B, lanes 3 and 6),
LAGE3 appears to enhance the PRAME-OSGEP interaction,
since substantially more OSGEP bound to PRAME when LAGE3
was also expressed (Fig 1B, compare lanes 1, 4, and 5 to lane 6,
and Fig. 1C, compare lane 4 to lanes 5 and 6). Finally, we
observed small amounts of TP53RK and TPRKB copurifying
with FLAG-PRAME dependent on both OSGEP and LAGE3
(Fig. 1B, lanes 1, 3, and 6).
Taken together, our results identified stable interactions
between PRAME and human orthologues of the EKC/KEOPS
complex.
EKC Purifications from K562 Cells
We next studied the expression patterns of EKC, Cullin2 ligase
subunits and PRAME in normal and cancer cells by querying the
GeneSapiens gene expression database [2]. This database contains
mRNA expression data of most human genes across almost 10000
array experiments from 175 healthy and pathological tissues.
Consistent with the literature, we found that PRAME is expressed
only in very few normal adult tissues while it is upregulated in
several cancers (Fig. S1). On the contrary, LAGE3, OSGEP,
TP53RK, TPRKB, and CUL2 seem to be expressed in most if not
all tissues (Figures S1, S2, S3, S4).
To explore further the protein-protein interactions between
PRAME and EKC, we generated K562 cell lines stably expressing
epitope-tagged versions of each of the four human predicted
human EKC subunits and performed protein complex purifica-
tions. As shown in Table 2, each EKC subunit co-purified with the
other three subunits of the complex, indicating that a complete
EKC complex is present in human cells.
Furthermore, TAG-OSGEP and TAG-LAGE3 (but not TAG-
TP53RK or TAG-TPRKB) copurified with significant amounts of
endogenous PRAME, consistent with TAG-PRAME purifications.
Remarkably, TAG-OSGEP and TAG-LAGE3 associated also
with Cullin2 ligase components (Table 2). The few peptides for
Cul2-PRAME components identified in TAG-TP53RK and
TAG-TPRKB eluates were not supported by western blot of the
same samples (not shown).
Interestingly, peptides matching the putative protein C14orf142
were specifically identified in eluates from OSGEP, LAGE3 and
TP53RK (Table 2). Similarly to LAGE3 and TPRKB, C14orf142
is predicted to be a small protein without clear structural domains.
It is tempting to speculate that this protein might constitute a novel
EKC interactor in human cells.
Although we did not identify peptides matching Cul2 by mass
spectrometry of TAG-OSGEP eluates, we did detect small
amounts of Cul2 by western blotting of the same samples (Fig. 2,
lane 6). Intriguingly, the level of Cul2 detected in TAG-OSGEP
eluates was substantially lower than in TAG-PRAME eluates
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Figure 1. PRAME interacts with OSGEP and LAGE3. (A) Coimmunoprecipitation assays verify the interaction of PRAME with the EKC subunits
OSGEP and LAGE3. Constructs expressing the indicated proteins were transiently transfected in 293T cells. Anti-TAG immunoprecipitations were
performed with rabbit HA antibody (Abcam). TAG-PRAME was detected with monoclonal anti-HA (Covance) and TTE-tagged proteins with
monoclonal BB2 (Diagenode) which recognizes the TY1 tag. The lower panel shows a scheme of the tagged proteins used (tags and coding
sequences are not on scale). (B-C) PRAME directly interacts with EKC complex through OSGEP and LAGE3. SF21 cells were co-infected with
baculoviruses expressing the indicated proteins. Anti-FLAG immunoprecipitations were performed, and total cell lysates and eluates were analyzed
by western blotting. Panels showing anti-HA immunoblots are from the same exposure of the same blot, as are the panels showing anti-cMyc
immunoblots. Asterisks indicate light chains of the antibodies used in the immunoprecipitation.
doi:10.1371/journal.pone.0042822.g001
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(Fig. 2, lanes 4 and 6), while Elongins B and C were present in
similar amounts in all purifications. These findings might indicate
that OSGEP establishes less stable interactions with Cullin2 as
compared to PRAME. Consistent with the mass spectrometry
results, TAG-PRAME did not copurify with TPRKB (Fig. 2, lane
4), while a clear band was detected in TAG-OSGEP eluates.
Our proteomic experiments show for the first time that a
complete EKC complex is present in human cells, and that the
OSGEP and LAGE3 subunits are present in a complex together
with PRAME and Cullin2 ligase components.
Topology of the human EKC complex
In order to study the topology of the interactions within the
human EKC complex, we expressed pairs of EKC subunits in the
baculovirus system and performed immunoprecipitations (Fig. 3).
As shown in figure 3, we observed reciprocal coimmunoprecipita-
tion of HA-LAGE3 and c-Myc-OSGEP and of HA-TPRKB and
c-Myc TP53RK, respectively. In addition, c-Myc TP53RK
copurified with HA-OSGEP upon anti-c-Myc immunopurifica-
tion, although this interaction was not detected in the reciprocoal
experiment, raising the possibility that the c-Myc epitope was
occluded and/or that binding of the antibody to the epitope
disrupts the interaction. Taken together, these experiments
established that human EKC has the linear configuration
LAGE3-OSGEP-TP53RK-TPRKB, consistent with the three-
dimensional structures of archael EKC orthologues that were
recently reported [28].
Interestingly, Mao et al. reported that archael Pcc1, the
orthologue of human LAGE3, forms highly interdigitated homo-
dimers and hypothesized that dimerization of Pcc1 might support
dimerization of the full EKC complex. Moreover, the crystal
structures indicated that one moiety of Pcc1 could bind only one
moiety of Kae1. We tested the dimerization properties of human
EKC using combinations of different epitope tags in transient
transfection experiments. As shown in figure 4A, FLAG-OSGEP
coimmunoprecipitated TTE-OSGEP when LAGE3 was cotrans-
fected (lane 4), establishing that multiple OSGEP moieties are
present in the same biochemical complex. Importantly, the
concomitant expression of PRAME did not affect these dimeriza-
tion properties (Fig. 4A, compare lanes 4 and 5). Taking into
consideration the structural information available for archaeal
EKC, our data suggest the formation of a tetrameric LAGE3-
OSGEP assembly (Fig. 4A).
In the same experiments, we noticed that OSGEP levels were
significantly lower in the absence of LAGE3 (Fig. 4A, compare
lanes 2 and 4), suggesting that the stability of OSGEP could be
critically dependent on interactions with other proteins. To
address this hypothesis, we transfected FLAG-OSGEP together
with each of the other EKC subunits or PRAME. Fig. 4B shows
that LAGE3, TP53RK and PRAME could all enhance the
stability of OSGEP. TPRKB did not alter OSGEP levels,
consistent with the absence of a direct interaction between these
two proteins. Interestingly, LAGE3 exerted the highest positive
effect, which correlates with the possibility to form tetrameric
LAGE3-OSGEP complexes, while TP53RK can bind only one
moiety of OSGEP. The finding that PRAME had a relatively
modest effect on OSGEP levels might reflect a less stable
interaction between OSGEP and PRAME, than between OSGEP
and TP53RK.
We investigated further the effect of LAGE3 on the protein
levels of OSGEP in transient transfection experiments with mutant
constructs. Based on the crystallographic structures of archael
EKC [28], we introduced point mutations in aminoacid residues
predicted to be involved in the protein-protein interactions
between OSGEP and LAGE3: R94A in OSGEP, and L129R or
T133R in LAGE3. Additionally, we generated OSGEP mutant
P35A/P36A (referred to as PPAA) and LAGE3 mutants K95A
and K109A, which are not predicted to contribute to the OSGEP-
LAGE3 interaction. As shown in figure 4C, the OSGEP mutant
R94A showed lower steady-state levels, which could not be
enhanced by co-expression of wild-type LAGE3, while OSGEP
PPAA behaved like the wild type. Similarly, levels of wild-type
OSGEP were not enhanced upon co-expression of either T133R
or L129R LAGE3 mutants, while the LAGE3 lysine mutants
behaved the same as wild type LAGE3.
Taken together, our data suggests (i) that the human EKC
complex is organized in the same way as its archaeal counterpart,
(ii) that dimerization of LAGE3 can mediate formation of higher
order structures containing at least two molecules of OSGEP, (iii)
that formation of these higher order structures is independent of
PRAME, and (iv) that the protein levels of OSGEP can be
significantly modulated by protein-protein interactions.
PRAME Bridges Cullin2 Ligases to the EKC Complex
We next studied the role of the Cullin2 complex in the
association of PRAME with EKC. Transient transfection exper-
iments showed that the interaction of PRAME with OSGEP and
LAGE3 does not require an intact BC-box, since a BC-box
defective PRAME (PRAME M2) coimmunoprecipitated OSGEP
and LAGE3 as efficiently as wild type PRAME (Fig. 5A).
Next, we purified TAG-LAGE3 protein complexes from
HeLaS3 cells, which express very low to undetectable levels of
endogenous PRAME. As expected, all EKC subunits copurified
with TAG-LAGE3, while no peptides were identified for PRAME
Figure 2. OSGEP interacts with PRAME and Cul2 ubiquitin
complex components. OSGEP interacts with PRAME and Cul2-EloBC
ligases. Immunoblot analysis of TAG-PRAME and TAG-OSGEP protein
complexes purified from K562 cells to verify the mass spectrometry
data. Mock purification was performed on wild type cells. 0.8% of input
and 33% of IP were separated on NuPage 4–12% gels. Tagged proteins
were detected with mouse HA antibody (Covance, top panel);
endogenous PRAME and TAG-PRAME were detected in the second
panel with affinity-purified PRAME antibody after staining for Cul2; the
other proteins were detected as indicated. Asterisks indicate protein A
that dissociated from the beads after elution.
doi:10.1371/journal.pone.0042822.g002
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(Table 2). Importantly, components of Cullin2 ligases did not
copurify with LAGE3 in these cells. The abundance of EKC
subunits was similar in the eluates from K562-TAG-LAGE3 and
HeLaS3-TAG-LAGE3 cells, consistent with similar protein levels
in the two cell lines.
These results, together with the finding that TAG-OSGEP and
TAG-LAGE3 associate with endogenous PRAME and Cullin2
ligase components in K562 cells, suggested that PRAME could be
involved in recruiting a Cullin2 ligase to the EKC complex.
To test this hypothesis, we knocked down endogenous PRAME
with stable transfection of retroviral constructs in K562-TAG-
OSGEP and K562-TAG-LAGE3 cell lines and performed
immunoprecipitations. Figure 5B clearly shows that downregula-
tion of PRAME significantly reduced the interaction between each
EKC subunit and Cul2, EloB and EloC, establishing that PRAME
is required for these interactions. As expected, the interaction of
TAG-OSGEP and TAG-LAGE3 with TPRKB was not affected
by PRAME knockdown. Notably, we found that the level of Cul2
detected in TAG-OSGEP eluates was substantially lower than in
TAG-LAGE3 eluates (Fig. 5B, lanes 1 and 4), despite similar
amounts of EloB and EloC. These results are similar to the
previous comparison between TAG-OSGEP and TAG-PRAME
eluates (Fig. 2, lanes 4 and 6).
Taken together, our data reveal that PRAME can bridge
Cullin2 ligases to the EKC complex (Fig. 5C).
Cul2-PRAME Ligases and EKC Subunits Co-localize to
Active Promoters
The yeast orthologues of OSGEP (Kae1p) and LAGE3 (Pcc1p)
have been reported to associate with the promoters and
transcribed regions of several genes in a transcription-dependent
manner [17]. Genome-wide chromatin immunoprecipitation
experiments revealed that PRAME and Cullin2 complex compo-
nents are specifically enriched at transcriptionally active promoters
that are also bound by the transcription factor NFY, and at nearby
enhancers [15].
In the absence of validated ChIP-grade antibodies against EKC
subunits, we generated K562 cell lines stably expressing the
proteins of interest fused to the TTE epitope tag (TY1-TY1-ER),
which can be efficiently and specifically used in ChIP-qPCR
experiments [15]. To determine whether human OSGEP and
LAGE3 are present on chromatin, we performed ChIP assays with
the BB2 antibody (which recognizes the TY1 tag) and tested a
panel of PRAME-bound promoters. The results in figure 6 clearly
show that all PRAME-bound promoters tested are efficiently
recovered in both K562-TTE-OSGEP and K562-TTE-LAGE3
cells, but not in parental K562 cells or control K562-TTE cells.
Our genomic experiments extend the biochemical interactions
to the chromatin environment, establishing that PRAME and
EKC subunits associate with the same promoter regions.
Discussion
We recently reported the first purifications of PRAME-
containing protein complexes by epitope-tagged immunoprecipi-
tations and mass spectrometry, which revealed that PRAME is a
BC-box substrate receptor component of Cullin2-based E3
ubiquitin ligases [15]. In the present study, we identified novel
interactions of Cul2-PRAME ligases with the human EKC/
KEOPS complex, we discovered that PRAME recruits ligase
components to EKC, and we showed that these proteins associate
Figure 3. Organization of human EKC complex. SF21 cells were co-infected with baculoviruses expressing the indicated proteins. Anti-FLAG
immunoprecipitations were performed, and total cell lysates and eluates were analyzed by western blotting. Interactions detected are summarized in
the diagram on the right. Panels showing anti-HA immunoblots are from the same exposure of the same blot, as are the panels showing anti-cMyc
immunoblots. Asterisk indicates light chains of the antibodies used in the immunoprecipitation.
doi:10.1371/journal.pone.0042822.g003
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Figure 4. OSGEP protein levels are modulated by protein-protein interactions. (A) Multiple OSGEP moieties are present in the same
complex. Constructs expressing the indicated proteins were transiently transfected in 293T cells. Total cell lysates and FLAG eluates were analyzed by
western blotting. A plasmid expressing GFP was cotransfected to control for the transfection efficiency. (B) OSGEP levels are affected by protein-
protein interactions. 293T cells were transfected with constructs expressing FLAG-OSGEP and the proteins indicated. The bar graph shows FLAG-
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OSGEP levels quantified by immunoblot with the Odyssey system (values are the average of two independent experiments). A plasmid expressing
GFP was cotransfected to control for the transfection efficiency. (C) and (D) LAGE3-OSGEP interface mutants decrease OSGEP protein levels. Transient
transfections in 293T cells with the mutant constructs indicated and immunoblot by Odyssey of total cell lysates. Graphs report intensities of FLAG-
OSGEP quantified with Odyssey (A.U., arbitrary units).
doi:10.1371/journal.pone.0042822.g004
Figure 5. PRAME recruits Cul2-EloBC ligases to EKC. (A) PRAME does not require an intact BC-box to interact with EKC components.
Coimmunoprecipitation assays as in Fig.1A with wild type and BC-box mutant M2 PRAME. (B) PRAME bridges Cullin2 ligases to EKC complex.
Immunoblot analysis as in Fig. 2 of TAG-OSGEP or TAG-LAGE3 immunoprecipitates with or without knock down of endogenous PRAME. Asterisk
indicates heavy chains of the antibodies used in the immunoprecipitation. (C) Models of the protein complexes architecture.
doi:10.1371/journal.pone.0042822.g005
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with the same promoter regions, strongly suggesting a functional
link between these complexes in the same pathway.
EKC is an ancient and extremely conserved complex with
orthologues in Archaea and Eukarya. It has been implicated in
telomere maintenance, transcriptional regulation, and t6A mod-
ification of tRNAs in yeast [16,17,20–22]. Our interaction data
support a linear architecture LAGE3-OSGEP-TP53RK-TPRKB
for the human EKC complex and dimerization around the
LAGE3 subunit, with two OSGEP moieties per complex. Our
results are fully consistent with recently reported crystal structures
of archaeal EKC proteins [28].
Consistent with the notion that all subunits contribute to the
activity of the complex, yeast EKC was reported to constitute a
stable entity. Downey et al. reported that deletion of either
Bud32p, Cgi121p, or Gon7p resulted in shorter telomeres. An
independent study found that Pcc1p was required for efficient
transcription of several yeast genes induced by pheromones or
galactose, and that deletion of Pcc1 inhibited the recruitment of
the SAGA and Mediator co-activators [17]. Dimerization of the
Pcc1p and Kae1p subunits was found to be necessary for cell
viability [28], and an intact interaction surface between Kae1p
and Bud32p was required for both the transcriptional and
telomere maintenance functions [29]. Most recently, the yeast
EKC complex was shown to be essential for a universal chemical
modification of tRNAs, called threonyl carbamoyl adenosine (t6A)
[20–22]. This modification occurs at position 37 of tRNAs
decoding ANN codons, including the first ATG of all protein-
coding mRNAs, and is required for efficient translation [23]. The
t6A modification activity was dependent on Pcc1p, the ATPase
activity of Kae1p, and the kinase activity of Bud32p, but not on
Cgi121p [22].
In our experiments, all human EKC orthologues co-purified
together and with similar abundance both in K562 and HeLaS3
cells, demonstrating for the first time that a complete and stable
EKC complex is present in human cells. However, we consistently
found that PRAME complexes contained primarily OSGEP and
LAGE3, and very low or undetectable levels of the other two
subunits TP53RK and TPRKB. This might reflect a PRAME-
mediated disruption of an otherwise stable EKC complex, or a
preferential binding of PRAME to an already existing (and
possibly dynamic) EKC submodule that was not previously
detected in yeast. It is tempting to speculate that PRAME could
mediate ubiquitination of EKC components via recruitment of the
Cul2 E3 ligase complex. In an attempt to test this hypothesis, we
performed ubiquitination assays upon transient transfections in
HEK293 cells in presence or absence of the proteasome inhibitor
MG132, and in vitro assays with purified proteins. As expected for
BC-box proteins, we detected polyubiquitin chains associated with
PRAME itself. However, the high background signals in these
assays did not allow us to detect a putative ubiquitination of EKC
subunits. Hence, our assays could not rule out that EKC might be
ubiquitination targets of Cul2-PRAME, and more efforts are
needed to test this hypothesis experimentally.
Interestingly, dynamic regulation of EKC components has been
reported: the kinase activity of Bud32p was repressed by
association with Kae1p [29], but promoted by binding to Cgi121p
[28]. Moreover, we found that the protein levels of OSGEP can be
significantly modulated by association with other proteins (Fig. 4),
with LAGE3 exerting the most pronounced positive effect,
followed by TP53RK and PRAME. Interestingly, the effect of
LAGE3 correlates with the formation of tetrameric complexes in
which an LAGE3 dimer binds two OSGEP moieties (Fig. 4A),
which are likely not in direct contact with each other [28].
The results of our transient transfection experiments and those
obtained using the baculovirus system suggested (i) that PRAME is
able to interact independently with LAGE3 and OSGEP and (ii) that
LAGE3 enhances the association of OSGEP with PRAME.
Considering the dimerization properties of the LAGE3-OSGEP
submodule, we therefore considered the possibility that multiple
PRAME moieties might be present in the same protein complex. In
this case, both epitope-tagged PRAME and endogenous PRAME
should be present in the same protein complex in K562-TAG-
PRAME cells, since the expression level of the two proteins were
similar. Contrary to this hypothesis, however, TAG-PRAME did
not co-immunoprecipitate endogenous PRAME in our experiments
(see Fig. 2 lane 4). Although we cannot formally exclude the
possibility that TAG-PRAME might compete with the endogenous
protein, our data are most consistent with the idea that there is only
one PRAME molecule per complex. Notably, our data suggest that
the interaction between PRAME and LAGE3-OSGEP is very
stable, since it was efficiently detected in all assays and despite the
long incubations times in our protein-complex purification proto-
cols. However, we cannot exclude that high levels of PRAME might
be required for the interactions to take place in cells. Taking into
Figure 6. OSGEP and LAGE3 are present at PRAME-bound promoters on chromatin. ChIP-qPCR experiments using BB2 antibody were
performed on K562 cells lines stably expressing TTE-OSGEP or TTE-LAGE3. As control for specificity, ChIPs were performed on the parental cells (wt)
and on cells transduced with the vector expressing the tag only (K562-TTE) using a panel of primer sets for PRAME biding sites. Values are expressed
as mean recoveries 6 standard deviation from three independent experiments.
doi:10.1371/journal.pone.0042822.g006
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account the published crystal structures of archaeal EKC, we
propose the models depicted in Figure 5C for the architecture of the
human EKC complex and the relationship between EKC and Cul2-
PRAME ligases. Further experiments are needed to confirm the
stoichiometry of PRAME-EKC complexes, and to characterize the
interaction surfaces involved.
Besides the functional experiments in yeast, no information is
available yet about EKC functions in other organisms. At present,
only studies focusing on single subunits of the human complex have
been reported. LAGE3 appears to be ubiquitously expressed, while
the two closely related LAGE1 and LAGE2 are cancer-testis
antigens with high expression confined to healthy testis and cancer
tissues [24]. Interestingly, expression of the N-terminal domain of
LAGE3 fused to the C-terminus of Pcc1p could partially rescue the
growth defects of a Pcc1 N-terminal mutant yeast strain, while full
length LAGE3 could not substitute for Pcc1 [17]. The OSGEP gene
was found expressed in all somatic tissues tested and it lies in a head-
to-head orientation with the tightly regulated APEX gene, which
encodes a multifunctional DNA repair enzyme [30]. Analyses of
their bidirectional promoter identified a CCAAT box crucial for
OSGEP transcription. Futhermore,OSGEP could partially rescue the
growth defects of the yeast kae1Dmutant [17], underlining degrees of
functional conservation. Human TP53RK was first cloned by cDNA
subtraction as an interleukin-2 upregulated gene in cytotoxic T-cells,
transcripts were detected in a number of normal tissues and cancer
cell lines, and it was shown to phosphorylate the human oncoprotein
p53 at Serine 15 [31]. Recombinant TP53RK expressed in bacteria
was found catalytically inactive, but incubation with COS-7 cell
lysates was sufficient to activate the enzymatic activity, suggesting
the need for activators and potentially protein interactors. The
kinase Akt/PKB was found to play a role in the activation of
TP53RK through phosphorylation of the Ser250 residue [32].
Underscoring a high level of functional homology, TP53RK could
partially rescue the growth phenotype of Bud32 deletion in yeast,
and Bud32 could interact with and phosphorylate human p53 in
vitro [33], although yeast does not possess a bone fide p53 homologue.
Human TPRKB was first isolated by a two-hybrid screen using
TP53RK as a bait, and was suggested to inhibit the binding of
TP53RK to p53 [34]. Expression of TP53RK was detected in the
high-PRAME expressing cell line K562 as well as in the low-
PRAME expressing cell line KG1 [34]. Gene expression data
obtained from the GeneSapiens database further suggests that EKC
subunits are expressed in most if not all human tissues (Figures S2,
S3, S4).
Considering the extreme conservation of EKC components
during evolution, it can be expected that at least some of the
functions and pathways already identified for this complex in yeast
could be valid for human cells as well. However, it cannot be
excluded that human EKC acquired additional, yet to be
identified functions during evolution. The absence of efficient
knock-down or knock-out models have so far hindered advanced
functional analysis of EKC in higher eukaryotes. Future studies
will have to address these issues, and in particular to understand
the connections between apparently different functions ascribed to
this complex, like phosphorylation of the p53 oncogene, chemical
modification of tRNAs, and physical association with promoter
regions.
Kae1p and Pcc1p have been found to associate with active
chromatin and to regulate expression of some of the yeast
promoters to which they are recruited [17]. A pcc1-4 mutation
prevented activation of GAL1 by impairing recruitment of the
SAGA histone acetyltransferase and mediator without affecting
recruitment of the activator Gal4p. In contrast, while Pcc1p was
recruited to the constitutively active PMA1 and the heat-shock
inducible HSP104 genes in a transcription-dependent manner,
transcription of these genes was not affected in the pcc1-4 mutant.
Our ChIP assays revealed that LAGE3 and OSGEP are also
present on chromatin and, in particular, that they colocalize with
PRAME at many of its target sites, consistent with our protein-
protein interaction data. Since neither PRAME nor EKC proteins
possess known DNA-binding domains, it is not clear whether they
can bind DNA directly. Genome-wide ChIP-seq experiments have
recently revealed that PRAME associates with transcriptionally
active NFY-regulated promoters and nearby enhancers [15].
Therefore, the transcription factor NFY might play a direct or
indirect role in the targeting of a Cul2-PRAME-EKC complex to
chromatin. It is also not clear whether there is a hierarchy in the
association of PRAME and EKC proteins with chromatin. In
order to address this point, we established stable cell lines with
downregulation of endogenous PRAME using the published
retroviral pRetroSuper system in either K562 wild type or
K562-TTE-LAGE3 cells and we performed ChIP experiments.
Unfortunately, despite a 70% downregulation of PRAME mRNA
levels, our preliminary results did not support a solid conclusion on
the hierarchy of binding to chromatin for PRAME and EKC.
More experiments, and likely in a different cell and knockdown
system, are required to address this point.
Importantly, EKC proteins have an ancient evolutionary origin
and seem to be ubiquitously expressed in adult tissues, while
PRAME appeared more recently in evolution, and its expression
seems to be tightly confined to particular developmental stages and
tissues and to be particularly deregulated in oncogenesis. These
characteristics are consistent with a model in which EKC can
associate with chromatin independently of PRAME. Only when
PRAME is expressed would a Cul2-PRAME ubiquitin ligase be
recruited to chromatin by virtue of specific protein-protein
interactions between LAGE3-OSGEP and PRAME.
In an attempt to study the putative function of EKC subunits on
target gene transcription, we established K562 cells with stable
downregulation of OSGEP or LAGE3 using pRetroSuper vectors
and performed genome-wide mRNA-seq analyses. Despite a 50–
80% knockdown efficiency for OSGEP and LAGE3, we did not
detect genes with significant expression changes when compared
to a GFP knockdown control. Our inconclusive data could of
course be the result of inefficient downregulation of the target
genes. Although the K562 cell line was successfully used to dissect
the protein-protein interaction network, we cannot exclude that
this cell line might not be suitable for the study of the finer putative
chromatin functions and signaling of EKC and PRAME.
The development of ChIP-grade antibodies against EKC
components will be a crucial step to address important questions
as to whether PRAME target sites are a subset of EKC sites (or
viceversa), and to address the functional relationships between
EKC, Cul2-PRAME ligases and NFY on transcriptional regula-
tion of target genes, and potentially other pathways like the
recently described modification of tRNAs.
Taken together, our data reveal a novel link between the human
oncoprotein PRAME and the ancient EKC complex. Our data
clearly show that PRAME can recruit Cullin2 ubiquitin ligases to
EKC, and that these complexes associate with the same genomic
regions, supporting a functional link in the same pathways. Our
results add a new twist to both PRAME and EKC biology and
provide an important contribution to understanding the molecular
mechanisms in which these proteins are active, both in healthy and
cancer cells.
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Materials and Methods
Cell Culture and Stable Cell Lines
HEK293T cells were cultured in DMEM and K562 and
HeLaS3 in RPMI medium (Gibco, Invitrogen) at 37uC in 5%
CO2; cell lines were obtained from ATCC. Both media were
supplemented with 5% Glutamax, 10% fetal bovine serum,
100 U/ml of penicillin, 100 mg/ml of streptomycin (Gibco,
Invitrogen). K562 and HeLaS3 stable cell lines were generated
with retroviral constructs as described [15]. Transient transfections
were performed with Lipofectamine2000 (Invitrogen).
Antibodies and Western Blot
Mouse monoclonal HA-12CA5 and Myc-9E11 were produced
in-house from hybridoma cultures, PRAME antibodies were
previously described [15]. Commercial antibodies used were:
mouse monoclonal FLAG-M2 (Sigma), c-Myc monoclonal (Roche
Applied Science), rabbit HA (Bethyl Laboratories), mouse
monoclonal HA.11 (Covance MMS-101P), rabbit Cul2 (Zymed
Laboratories 51-1890), mouse ElonginC (BD Transduction
Laboratories 610760), goat ElonginB (Santa Cruz P-16, sc-
23407), mouse TPRKB (Abcam ab68245), mouse BB2 against
TY1 tag (Diagenode), GFP (Santa Cruz). Proteins were separated
by conventional SDS-PAGE or NuPAGE 4–12% Bis-Tris gels
(Invitrogen) run with MES buffer. Western blots were visualized
by ECL (GE Healthcare) or Odyssey (LiCor) for quantification.
Plasmids and Cloning
A modified version of the retroviral vector LZRS(Zeo) with an
improved MCS was made by ligation of a synthetic oligo to
generate LZRSn(Zeo). The sequence coding for the StrepII-TEV-
MYC-3xHA tag was excised with BamHI and NotI from
pcDNA5-TAG-PRAME and subcloned in LZRSn(Zeo) to gener-
ate LZRSn-TAG, where the EcoRI site is in the same frame as in
the pTTE retroviral vector [15].
The TTE cassette was subcloned from pTTE [15] to
pcDNA3.1(+) using BamHI and XhoI sites to generate pcDNA-
TTE for transient transfections.
Full-length human OSGEP was amplified by PCR from cDNA
prepared from K562 cells to generate a NotI-EcoRI-OSGEP-SalI
fragment, which was cloned into pFLAG-CMV2 (pFLAG-
OSGEP). OSGEP was subsequently subcloned as an EcoRI-SalI
fragment into the EcoRI and XhoI sites of pTTE and pcDNA-
TTE, to generate pTTE-OSGEP and pcDNA-TTE-OSGEP,
respectively. OSGEP was cloned as a NotI-SalI fragment
downstream the TAG in LZRSn(Zeo), generating LZRSn-TAG-
OSGEP.
LAGE3 CDS was obtained from Invitrogen, PCR amplified to
introduce EcoRI and XhoI sites, and subcloned in the same sites of
pTTE, pcDNA-TTE, and LZRSn-TAG-LAGE3.
Full-length TP53RK/PRPK and TPRKB were amplified by
PCR from cDNA of K562 cells and subcloned as EcoRI and XhoI
fragments to generate all constructs used.
Mutagenesis to generate OSGEP and LAGE3 mutants was
performed using the QuikChange II XL site-directed mutagenesis
kit (Stratagene) according to the manufacturer’s instructions.
All constructs were checked by sequencing.
Purification of Protein Complexes and Mass
Spectrometry Analysis
Protein complex purifications and mass spectrometry were
performed from nuclear extracts (unless otherwise indicated)
essentially as described [15]. For HeLaS3 cells the protein
extraction protocol was performed with a tighter douncer (pestle
B). The quality of cytoplasmic and nuclear extractions were tested
by immunoblotting of equivalent volume fractions for alpha
tubulin (cytoplasmic marker) and HDAC2 (nuclear marker).
For TAG-PRAME purifications with MYC antibody, about
10 ml of protein extracts (,100 mg) were incubated with 50 ml
(MYC1 experiment) or 600 ml (MYC2 experiment) of crosslinked
MYC beads and peptide elution was performed. For protein
complex purifications with HA antibody, about 5–6 ml of protein
extracts were incubated with 600 ml HA-12CA5 crosslinked beads
and acidic glycine (pH 2.9) was used for elution.
The data analysis steps of peptide-to-protein remapping and
emPAI calculation were automated with a PERL script to
generate output tables of unique protein IDs with peptide
frequencies and emPAI values for each samples (see Protocol S1
and Analysis Script S1). The protein list was manually filtered to
discard proteins identified in the control samples (false positives).
Expression of Recombinant Proteins in Sf21 Insect Cells
cDNAs encoding wild type or mutant PRAME, OSGEP,
LAGE3, TP53RK and TPRKB were subcloned into pBAcPAK 8
and recombinant baculoviruses were generated. SF21 cells were
cultured at 27uC in SF-900 medium supplemented with 10% fetal
bovine serum. SF21 cells were co-infected with the recombinant
baculoviruses indicated in the figures. 50 hours after infection, cells
were collected, lysed, and processed as described [35].
ChIP and qPCR
Chromatin harvests, ChIPs and qPCR analyses were performed
as previously described [15]. The BB2 antibody recognizing the
TY1 epitope (Diagenode) was used to ChIP TTE-tagged proteins
from K562 stable cell lines.
Supporting Information
Figure S1 Detailed expression profiles of MAG, TBP,
CUL2, and PRAME from the GeneSapiens database.
Normalized relative gene expression levels in healthy (green) and
cancer (red) tissues are plotted as boxplots. MAG and TBP are
shown as references: MAG is a known neuronal marker gene and
shows an expression profile that is highly specific for the central
nervous system. On the contrary, TBP is a ubiquitously expressed
gene. Similary to TBP, the expression profile of CUL2 indicates
ubiquitous expression in both healthy and cancer tissues. On the
contrary, PRAME is expressed mainly in the healthy testis, and is
upregulated in a number of cancers.
(TIF)
Figure S2 Detailed expression profiles of EKC subunits
from the GeneSapiens database. Normalized relative gene
expression levels in healthy (green) and cancer (red) tissues are
plotted as boxplots. The expression profiles of LAGE3, OSGEP,
TPRKB, and TP53RK indicate expression in all or most healthy
and cancer tissues.
(TIF)
Figure S3 Gene expression correlation plots between
PRAME and subunits of Cul2 ligases or the EKC
complex. Co-expression plots were generated from the GeneSa-
piens database for PRAME and CUL2 or each of the EKC
subunits. Correlations plots are shown for healthy tissues (A), and
cancer tissues (B). The plots indicate that the expression of the
genes tested do not correlate linearly. In particular, a large number
of samples are characterized by low or no PRAME expression,
while CUL2 and EKC subunits are expressed at higher levels.
(TIF)
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Figure S4 Gene expression correlation plots between
subunits of Cul2 ligases and subunits of the EKC
complex. Co-expression plots were generated from the GeneSa-
piens database for CUL2 and TCEB1, and couples of EKC
subunits. Correlations plots are shown for healthy tissues (A), and
cancer tissues (B).
(TIF)
Protocol S1 Detailed protocol for comparative analyses
of mass spectrometry data.
(DOC)
Analysis Script S1 PERL script mapPep2Prot_v0.3.pl for
analysis of mass spectrometry data.
(PL)
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